Association of single nucleotide polymorphism Lys198Asn of the endothelin-1 gene with it’s concentration in the serum of multiple myeloma patients
https://doi.org/10.25557/2073-7998.2023.03.54-58
Abstract
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of abnormal plasma cells. Patients with MM have a baseline cardiovascular disease (CVD) risk of 54–74%. An important role in the development and/or progression of CVD is played by endothelial dysfunction (ED), which is based on an imbalance, in particular, between the synthesis and secretion of vasoconstrictors and vasodilators. In connection with the predictive and preventive focus of medicine, it has become relevant to study the genetic predisposition to the development of ED. We have studied the association of genetic variants of endothelin-1 gene (rs5370) with the concentration of endothelin-1 (ET-1) in the blood serum of patients with newly diagnosed MM before the start of anticancer therapy. As a result of the study, the following distribution of genetic variants in the study group was revealed: the wild variant was 13.64%, the minor variant was 29.55%, and the heterozygous variant was 56.82%. While in the control group it was as follows: 40.00%, 24.44% and 35.56%, respectively. Patients with MM had higher serum ET-1 concentrations when compared with patients without MM.
About the Authors
E. V. Mordvinova
Samara State Medical University
Russian Federation
Russian Federation
89, Chapaevskaya st., Samara, 443099
A. S. Sustretov
Institute of Experimental Medicine and Biotechnology
Russian Federation
Russian Federation
20, Gagarina st., Samara, 443079
T. P. Mironova
Samara State Medical University
Russian Federation
Russian Federation
89, Chapaevskaya st., Samara, 443099
I. L. Davydkin
Samara State Medical University
Russian Federation
Russian Federation
89, Chapaevskaya st., Samara, 443099
K. V. Naumova
Samara State Medical University
Russian Federation
Russian Federation
89, Chapaevskaya st., Samara, 443099
T. Yu. Stepanova
Samara State Medical University
Russian Federation
Russian Federation
89, Chapaevskaya st., Samara, 443099
References
1. Cowan A.J., Allen C., Barac A., et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncology 2018; 4 (9): 1221-7. DOI: 10.1001/jamaoncol.2018.2128
2. Offidani M., Corvatta L., Morè S., Olivieri A. Novel Experimental Drugs for Treatment of Multiple Myeloma. J Exp Pharmacol. 2021; 13: 245-264. DOI: org/10.2147/JEP.S265288
3. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12 (9): 547-58. DOI: 10.1038/nrcardio.2015.65
4. Siegel R., DeSantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62 (4): 220-41. DOI: 10.3322/caac.21149
5. Briasoulis A., Chasouraki A., Sianis A., et al. Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents. J Cardiovasc Dev Dis. 2022; 9 (3): 66. DOI: 10.3390/jcdd9030066
6. Strongman H., Gadd S., Matthews A., et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019; 394 (10203): 1041-1054. DOI: 10.1016/S0140-6736(19)31674-5
7. Leerink J.M., de Baat E.C., Feijen E.A.M., et al. Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol. 2020; 2 (3): 363-378. DOI: 10.1016/j.jaccao.2020.08.006
8. Waxman A.J., Clasen S., Hwang W.T, et al. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4 (3): e174519. DOI: 10.1001/jamaoncol.2017.4519
9. Matsuzawa Y., Kwon T.G., Lennon R.J., et al. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2015; 4 (11): e002270. DOI: 10.1161/JAHA.115.002270
10. Deanfield J.E.., Halcox JP., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115(10): 1285-95. DOI: 10.1161/CIRCULATIONAHA.106.652859
11. Böhm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007; 76 (1): 8-18. DOI: 10.1016/j.cardiores.2007.06.004
12. Hsieh H.J., Liu C.A., Huang B., et al. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J Biomed Sci. 2014; 21 (1): 3. DOI: 10.1186/1423-0127-21-3.
13. Brown G.R., Hem V., Katz K.S., et al. Gene: a gene-centered information resource at NCBI. Nucleic Acids Res. 2015; 43(Database issue): D36-42. DOI: 10.1093/nar/gku1055
14. Jin J.J., Nakura J., Wu Z., et al. Association of endothelin-1 gene variant with hypertension. Hypertension. 2003; 41 (1): 163-7. DOI: 10.1161/01.hyp.0000043680.75107
15. Nepal G., Ojha R., Dulal H.P., Yadav B.K. Association between Lys198Asn polymorphism of endothelin-1 gene and ischemic stroke: A meta-analysis. Brain Behav. 2019; 9 (10): e01424. DOI: 10.1002/brb3.1424
16. Dubovyk Y.I., Oleshko T.B., Harbuzova V.Y., Ataman A.V. Positive Association between EDN1 rs5370 (Lys198Asn) Polymorphism and Large Artery Stroke in a Ukrainian Population. Dis Markers. 2018: 1695782. DOI: 10.1155/2018/1695782
17. Treiber F.A., Barbeau P., Harshfield G., et al. Endothelin-1 gene Lys198Asn polymorphism and blood pressure reactivity. Hypertension. 2003; 42 (4): 494-9. DOI: 10.1161/01.HYP.0000091266.41333.15
18. Smiianova Y.O., Pristupa L.N., Harbuzova V.Y., Harbuzova Y.A. The association of LYS198ASN -polymorphism of endothelin-1 gene (EDN1) with development of arterial hypertension in ukrainian population. Wiad Lek. 2019; 72 (4): 568-574.
Review
For citations:
Mordvinova E.V., Sustretov A.S., Mironova T.P., Davydkin I.L., Naumova K.V., Stepanova T.Yu. Association of single nucleotide polymorphism Lys198Asn of the endothelin-1 gene with it’s concentration in the serum of multiple myeloma patients. Medical Genetics. 2023;22(3):54-58. (In Russ.) https://doi.org/10.25557/2073-7998.2023.03.54-58
Views:
186
Email this article 